➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Boehringer Ingelheim
McKinsey
AstraZeneca
Medtronic

Last Updated: January 18, 2021

DrugPatentWatch Database Preview

Details for Patent: 7,384,649

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,384,649 protect, and when does it expire?

Patent 7,384,649 protects INBRIJA and is included in one NDA.

This patent has nine patent family members in eight countries.

Summary for Patent: 7,384,649
Title:Particulate compositions for pulmonary delivery
Abstract: This invention concerns an improved particulate composition for delivering a drug to the pulmonary system. Applicants disclose a method of identifying an optimal form of aerodynamically light particles which are highly dispersible. The particles of the instant invention are made by creating hollow, spherical drug particles (i.e., progenitor particles) that collapse in the process of particle formation, leading to wrinkled, thin-walled drug particles of very low envelope density. Additionally, Applicants have found that such particles are especially optimal for inhaled aerosols when the surface area parameter (.sigma.) is greater than 2, optimally greater than 3.
Inventor(s): Batycky; Richard P. (Newton, MA), Edwards; David A. (Boston, MA), Lipp; Michael M. (Framingham, MA)
Assignee: Advanced Inhalation Research, Inc. (Cambridge, MA)
Application Number:11/633,750
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Delivery;

Drugs Protected by US Patent 7,384,649

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,384,649

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2002352836   Start Trial
Canada 2465675   Start Trial
Denmark 1455755   Start Trial
European Patent Office 1455755   Start Trial
Spain 2415654   Start Trial
Japan 2005511628   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Baxter
Harvard Business School
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.